liraglutide a glp 1 FDA approves first generic once-daily injection SCALE: the trial that opened

"I really haven't gotten any weaker," Davidson said

Table 3 provides an overview of experimental and clinical studies investigating the pathogenic and mechanistic roles of NETs across infectious, autoimmune, cardiovascular, and neoplastic diseases

Promising effects beyond weight loss Researchers are currently studying the effect of GLP-1s on a wide range of conditions beyond diabetes, obesity, and heart disease, including renal, hepatic, neurological, and substance-use disorders

[1] Important safety considerations include the risk of hypoglycaemia when combined with insulin or sulfonylureas, potential dehydration and acute kidney injury with severe gastrointestinal symptoms, and for semaglutide specifically, possible worsening of diabetic retinopathy in those with pre-existing disease

Mental tools to cope with stress and boost resilience are invaluable when stopping GLP-1s